Show me the money

Houston esports company closes $6.8 million series A round led by local investor

Chris Buckner has secured a $6.8 million series A round for his Houston-based esports company thanks to support from a local investment firm. Courtesy of Mainline

A Houston software company is cashing in on the growing esports industry with a multimillion-dollar fundraising round led by a local investor.

Mainline, which specializes in esports tournament software and management, closed its series A at $6.8 million. Houston-based Work America Capital led the round, and Mainline will use the funds to grow its platform, event management customer base, and marketing efforts, as well as to hire developers, marketing, and sales talent.

"The world of esports and gaming is exploding; however, continuity in tournament organization is lacking, keeping the sport from really taking off in other viable and exciting markets," says Chris Buckner, Mainline CEO, in a news release. "Mainline gives brands the tools they need to run powerful esports programs that will evolve the quickly maturing industry to the benefit of players, students, and the greater esports ecosystem."

Mainline, which spun off its sports engagement business earlier this year into a company now called Truss, created a white-labeled tournament platform for esports that's used by various clients across the industry and was instrumental to ESPN's inaugural Collegiate Esports Championship that was hosted in Houston earlier this year.

Work America Capital has supported sports technology in town before — including Houston-based Integrated Bionics, which has developed a GPS- and video-optimized sensor used by athletes around the world.

"As with any industry that takes off like a rocket, problems arise that must be solved through innovation," says Mark Toon, managing partner of Work America Capital, in the release. "Mainline is standardizing, organizing and optimizing the esports industry, paving the way for more players, more teams, more money and bigger, better tournaments."

Mainline is focused on expanding its services as esports continues to grow. According to the release, the total industry revenue for this year is expected to reach $1.1 billion worldwide, and viewership numbers have jumped from 335 million to 454 million in just two years.

"The strategic vision of Mainline puts them in the driver's seat with a consistent platform across amateur, collegiate and professional competitions," says Toon. "Given Mainline's partnerships and customers, they have paved a way to grow quickly across all sports and into other markets. We are excited to dedicate our time, resources and capital to the company."


Mainline has created a white-labeled software for esports gaming and tournaments. Courtesy of Mainline

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted